#6090 Background: It has been said that the high incidence of breast cancer within family lines could be investigated efficiently from genetic and environmental aspects. There could be a strong enough relationship between various carcinogenic factors and these family members. In this study, we examined the clinical and pathological characteristics of breast cancer among patients with a family history.
 Patients and Methods: We put the definition of 'Positive for a family history (FH+)' for patients who had one or more members within three generations apart from the proband. Patients with family history of breast cancer were selected out of 10506 patients who were treated in our hospital between 1962 and 2007.
 Results: There were 1272 cases in FH+ and 9234 cases in 'Negative for a family history (FH-)' group. Distribution within the family line showed the highest percentage for sisters at 37%, aunts at 25% and a mother at 25%. The family history positive breast cancer patients were around 5% in 1960-1970 although the number increased up to 18% in 2007. There was similar increasing pattern in Europe and America. The survival rate had no significant difference between FH+ and FH- statistically, but the trend was toward a better prognosis in FH+ cases. There was no relationship between family history and body mass index (BMI). The outbreak of contralateral breast cancer of FH+ was significantly higher than FH-. FH+ patients had significantly higher prevalence of a mastopathy compare to FH- patients. As for the history of other cancer species, the FH+ breast cancer patients within first generation apart from the proband had significantly higher chances compared to FH- patients.Conclusion: The breast cancer patients with family history require more detail examinations especially for the development of contralateral breast cancer. Also carcinomatous examinations are important other than breast cancer to those patients who are in the first generation apart from the proband. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6090.

No abstract

No abstract

No abstract

Background: This study assessed the efficacy of immersive virtual reality (VR) as an adjunct in the management of treatment-related anxiety and depression among breast cancer outpatients undergoing chemotherapy at the University of the Philippines -Philippine General Hospital Cancer Institute. Methods:In this open-label phase II randomized control trial, participants were randomly assigned into two groups during their first cycle of chemotherapy e the intervention group who were subjected to immersive VR experience using VR Box 3D goggle sets plus standard-of-care and the control group who received standard-ofcare only. Anxiety and depression scores of at-risk breast cancer patients were measured using the Hospital Anxiety and Depression Scale -Pilipino (HADS-P) questionnaire before and after chemotherapy. The influence of clinico-demographic factors on the mean difference of HADS-P scores was explored. Pre-and postchemotherapy blood pressures, heart rates, and respiratory rates were also determined. Results:The investigators were able to screen 114 patients and 65.8% (n¼75) had a HADS-P score of 11. The proportion of patients who were at-risk to develop treatment-related anxiety and depression was 73.5% (n¼50) and 22.1% (n¼15), respectively. A total of 68 patients were included in the randomization. Statistically significant mean differences of j-2.71j and j-4.74j (p<0.05) in the pre-and postchemotherapy HADS-P scores between the control group and intervention group were reported. Changes in mean arterial pressures, heart rates, and respiratory rates pre-and post-chemotherapy were not statistically significant.Conclusions: In this study, the investigators observed that immersive VR could potentially decrease the level of treatment-related anxiety and depression of at-risk breast cancer outpatients undergoing chemotherapy.